Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Advisory Panel Endorses Asthmatx's Alair Device For Severe Asthma

This article was originally published in The Gray Sheet

Executive Summary

Asthmatx's Alair bronchial thermoplasty system should be approved for severe asthma that is not adequately controlled by drugs, according to FDA's Anesthesiology and Respiratory Therapy Devices Panel

You may also be interested in...

Asthmatx Debuts Alair For Severe Asthma Following PMA Approval

Asthmatx is initiating a "focused launch" of its Alair bronchial thermoplasty system after receiving PMA approval April 27, according to CEO Glen French

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts